Moreover, we used the online tool GEPIA to analyze the prognostic values of NAT1 and NAT2 expression and found that lower levels of NAT1 and NAT2 expression were correlated with poorer prognosis in COAD patients. This evidence concerns the gene NAT1 and colon adenocarcinoma.